Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Jade Biosciences Earnings Call: Key Takeaways

Jade Biosciences is advancing its pipeline with Jade 301 for Dermatomyositis, leveraging preclinical data showing 2.5-fold higher affinity and 8-fold greater potency than competitor Dazookibart, with a cash runway extending into Q4 2028.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceHigh confidence in Jade 301's best-in-class potential and subcutaneous delivery advantages.
Demand VisibilityTargeting 50,000 US Dermatomyositis patients; competitor pricing noted at $420,000 annually.
Segment GrowthJade 101 Phase 2 data 2027; Jade 201 interim data 2027.
Capex & DebtCash runway expected into fourth quarter of 2028 for all programs.
RegulatoryPhase 3 Jade 101 initiation H1 2027 pending FDA alignment.
CommentaryStrategic focus on subcutaneous delivery to reduce treatment burden versus IV competitors.
New LaunchesJade 301 Phase 1 healthy volunteer study initiating Q4 2026.

Outlook

Phase 1 healthy volunteer data for Jade 301 expected in second half of 2027.

Risks

Management pivoted to vague language regarding post-Phase 1 development pathways and specific steroid tapering trial designs.

Source

The company's earnings call, NASDAQ: JBIO, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Jade Biosciences, Inc.: key numbers

Share price
$15.34Close, Nov 16
Market cap
$1.06B
Shares outstanding
69.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Jade Biosciences, Inc.

All →
7:30 AM ET 10-Q
Financial Results ▶ Call

Jade Biosciences Q3 2026 Results: Net Loss of $35.1M, Loss Widens

Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.

Key figure
Net loss $35.1M
7:21 AM ET 8-K
Financial Results

Jade Biosciences Financial Results

Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.

Term
Q3 2026

“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”

Tom Frohlich, Chief Executive Officer of Jade
7:14 AM ET 8-K
Clinical Trial Data

Jade Biosciences Clinical Trial Data

Jade Biosciences announced preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data demonstrated high-affinity binding, potent inhibition of downstream signaling, and a differentiated pharmacokinetic profile supporting infrequent subcutaneous dosing. The company expects to initiate a Phase 1 clinical trial in healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.